MONTVALE, N.J.--(BUSINESS WIRE)--Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced two key additions to the company’s management team. Kathleen Boziwick, previously employed by Pfizer in a variety of commercial development roles for 18 years, has joined ITI as Vice President, Commercial Development. Michael Lusty, Ph.D., who brings extensive experience in the development of both pharmaceuticals and medical devices, joins the company as Vice President, Pharmaceutical Development.
